The newly available injectable option gives people with early Alzheimer’s disease a more convenient way to begin treatment outside a clinic
Cambridge, Massachusetts, 27 August 2026 – A new option for Alzheimer’s disease treatment is now available in the United States, offering eligible patients a way to begin therapy from home. Eisai and Biogen have announced the U.S. availability of Leqembi Iqlik, a once-weekly injectable form of lecanemab for adults with early Alzheimer’s disease. The treatment is designed for people with mild cognitive impairment or mild dementia caused by Alzheimer’s disease.
The development marks a shift in how some Alzheimer’s treatments can be delivered. Instead of requiring an intravenous infusion at a healthcare facility to begin therapy, Leqembi Iqlik uses an autoinjector that can be administered under the skin. Patients or their caregivers can receive the treatment at home after appropriate instruction and medical guidance.
For the initial treatment period, the approved dose is 500 milligrams once a week. This is given as two consecutive 250 milligram injections, with each injection taking about 15 seconds to administer. The same product can later be used for maintenance treatment at a dose of 360 milligrams once a week after 18 months of intravenous or subcutaneous treatment.
The new option also provides greater flexibility during treatment. Patients can receive Leqembi through intravenous infusion or subcutaneous injection and can switch between the two methods when medically appropriate. This could make it easier for patients and their caregivers to manage treatment around everyday responsibilities, travel, and other commitments.
Leqembi, also known by its generic name lecanemab, is an amyloid beta-directed antibody. It is designed to target amyloid beta, a protein that can build up in the brain and form plaques associated with Alzheimer’s disease. The FDA has approved the treatment for adults with Alzheimer’s disease, with the treatment focused on patients in the early stages of the condition.
The FDA approval for the at-home starting dose came in July 2026. The agency noted that the effectiveness of the subcutaneous formulation is supported by the established clinical performance of the intravenous formulation, along with evidence showing comparable effects in the body and similar reductions in amyloid plaques.
While the new delivery method offers convenience, treatment still requires medical oversight. Patients need brain magnetic resonance imaging before starting therapy and at specified points during treatment to monitor for amyloid-related imaging abnormalities, commonly known as ARIA. These abnormalities can involve temporary brain swelling or small areas of bleeding. Headache, infusion-related reactions, and ARIA are among the reported common side effects associated with Leqembi.
The introduction of Leqembi Iqlik could also reduce some of the practical challenges associated with regular infusion appointments. At-home administration may reduce time spent in medical facilities and lower some of the resources needed for infusion preparation and monitoring. For families supporting someone with early Alzheimer’s disease, that added flexibility may make long-term treatment easier to manage.
The arrival of Leqembi Iqlik reflects a broader movement in healthcare toward treatment options that combine medical effectiveness with greater convenience. As Alzheimer’s research continues to develop, easier methods of delivering approved therapies could become increasingly important for patients, caregivers, and healthcare providers.
For people living with early Alzheimer’s disease, the availability of a once-weekly autoinjector does not change the need for careful medical assessment and monitoring. However, it gives eligible patients another way to receive an established Alzheimer’s treatment while potentially reducing the burden of frequent clinic visits.
